Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate

Leguay, Zoé; Bourneau‐Martin, Delphine; Pellier, Isabelle; Louët, Hervé Le; Drablier, Guillaume; Lagarce, Laurence; Lainé-Cessac, Pascale

doi:10.1002/pbc.25797

Cited by 9 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 Recently, a few reports of hypersensitivity reactions with etoposide phosphate have also emerged. 7,9,17,18 There is conflicting data in the literature regarding incidence of etoposide hypersensitivity reactions in adults and children. According to the Food and Drug Administration (FDA) approved product label, hypersensitivity occurs in up to 2% of patients.…”

Section: Introductionmentioning

confidence: 99%

“…8,11,16,20 The incidence of hypersensitivity with etoposide phosphate is largely unknown and limited to case reports in adults and pediatrics. 7,9,17,18 Although the FDA prescribing information includes a warning for etoposide phosphate hypersensitivity reactions, it does not specify incidence. 6 Two pediatric case reports described a 14-month-old girl who developed a hypersensitivity reaction to both etoposide and etoposide phosphate and a five-year-old girl who experienced a hypersensitivity reaction to etoposide phosphate and subsequently tolerated etoposide.…”

Section: Introductionmentioning

confidence: 99%

“…6 Two pediatric case reports described a 14-month-old girl who developed a hypersensitivity reaction to both etoposide and etoposide phosphate and a five-year-old girl who experienced a hypersensitivity reaction to etoposide phosphate and subsequently tolerated etoposide. 9,18 The current literature provides insufficient evidence to determine the comparative risk of hypersensitivity between etoposide phosphate and etoposide.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies

Stockton

Nguyen

Zhang

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Etoposide is critical in treating pediatric cancers, although hypersensitivity can be severe and treatment-limiting. Reported rates of hypersensitivity range from 2% to 51%. Hypersensitivity data for etoposide phosphate, a newer product, are lacking. The primary objective of this study was to assess etoposide and etoposide phosphate hypersensitivity incidence. Secondary objectives included evaluation of potential risk factors for hypersensitivity and strategies to prevent recurrence. Methods This retrospective cohort study evaluated pediatric patients who received initial etoposide phosphate or etoposide dose between August 2012 and July 2017. The primary outcome was documentation of hypersensitivity within four months of initial dose. Potential risk factors evaluated included age, allergies, dose, infusion rate, infusion concentration, and premedication. Results Of 246 patients, hypersensitivity reactions occurred in five of 54 patients (9.3%) who received etoposide phosphate and 52 of 192 patients (27.1%) who received etoposide ( p = 0.0061). For etoposide, the mean initial infusion rate was 64.6 ± 40.9 mg/m2/h for patients with hypersensitivity and 49.5 ± 33.4 mg/m2/h without hypersensitivity ( p = 0.0886). Etoposide phosphate rate was not associated with hypersensitivity. Recurrent hypersensitivity occurred in one of nine patients (11.1%) who received etoposide desensitization and one of 38 patients (2.6%) who changed formulation to etoposide phosphate. Conclusions Etoposide was associated with more hypersensitivity than etoposide phosphate in pediatric patients. Etoposide hypersensitivity was associated with higher infusion rates, but not etoposide phosphate. Differences in hypersensitivity incidence and infusion rate influence indicate a formulation-effect. Etoposide hypersensitivity recurrence may be prevented by changing to etoposide phosphate formulation. During etoposide phosphate shortages, etoposide desensitization may prevent recurrent hypersensitivity.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies

Stockton

Nguyen

Zhang

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Based on available data, the proposed explanation of hypersensitivity reaction to etoposide phosphate was hypersensitivity to dextran 40, the vehicle used. 12 Dextran was used in both vascular surgery and plastic and reconstructive surgery for its capacity to reduce platelet aggregation and to promote blood flow in the microcirculation. 15 Severe hypersensitivity reactions to dextran have been highlighted since the 1960s.…”

Section: Discussionmentioning

confidence: 99%

Severe hypersensitivity reaction to etoposide phosphate: A case report

Cotteret

Rousseau

Zribi

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…28 No entanto, estão já descritos casos de hipersensibilidade ao etoposido fosfato, após reação prévia ao etoposido, em crianças 29 e em adultos, 30 mas também sem exposição prévia ao etoposido. 31 Outras abordagens possíveis em caso de hipersensibilidade ao etoposido consistem na exclusão deste fármaco do protocolo terapêutico, com os riscos inerentes de insucesso terapêutico, 2 ou a re-infusão após pré-tratamento com anti-histamínico e/ou corticosteroide e ritmo de infusão mais lento. 32…”

Section: Etoposido (Vp-16)unclassified

Reações de Hipersensibilidade a Citostáticos em Idade Pediátrica

Castro

Morais‐Almeida

2018

Gaz Med

View full text Add to dashboard Cite

As reações de hipersensibilidade a antineoplásicos podem variar entre reações ligeiras a reações anafiláticas fatais e podem ser desencadeadas virtualmente por qualquer citostático. Na ausência de uma alternativa viável, a dessen-sibilização pode ser a única forma de prosseguir a terapêutica. Pretendeu-se com este artigo rever a literatura inde-xada publicada sobre este tema, de modo a caracterizar as reações de hipersensibilidade associadas aos fármacos citostáticos mais frequentemente utilizados em idade pediátrica e a sua abordagem.

show abstract

Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate

Cited by 9 publications

References 8 publications

Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies

Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies

Severe hypersensitivity reaction to etoposide phosphate: A case report

Reações de Hipersensibilidade a Citostáticos em Idade Pediátrica

Contact Info

Product

Resources

About